.Charles Baum, M.D., Ph.D., who managed Mirati Therapies' $ 5.8 billion sale to Bristol Myers Squibb in 2015, is taking the helm of younger biotech Terremoto Biosciences.Baum's "considerable experience in medication advancement, and proven performance history in advancing high-impact medicines, are going to contribute," outbound CEO Peter Thompson, M.D., pointed out in a July 25 release. Thompson will retain his chair as board chairperson..Baum, a skilled physician-scientist, was the founder, president and also chief executive officer of oncology-focused Mirati. Prior to that, he helped cultivate cancer drugs at Pfizer as well as Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will certainly act as CEO at Terremoto, a business developing tiny molecules to target disease-causing proteins-- like those located in cancerous growth tissues-- making use of covalent connects. Existing treatments that use covalent bonds mainly target the amino acid cysteine. However, of the twenty amino acids that comprise proteins, cysteine is the least usual. Terremoto is instead targeting one of the necessary amino acids, lysine, which is actually located in almost all proteins.Through targeting lysine as well as other amino acids, Terremoto plans to treat previously undruggable ailments and make first-in-class medicines..The biotech, based in South San Francisco, increased $75 thousand in collection A backing in 2022. A little greater than a year eventually, the biotech much more than doubled that amount in a $175 million collection B.